Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 656

1.

Diagnostic markers for early detection of ovarian cancer.

Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, Tenthorey J, Leiser A, Flores-Saaib R, Yu H, Azori M, Rutherford T, Schwartz PE, Mor G.

Clin Cancer Res. 2008 Feb 15;14(4):1065-72. doi: 10.1158/1078-0432.CCR-07-1569. Epub 2008 Feb 7. Erratum in: Clin Cancer Res. 2008 Aug 15;14(16):5308. Clin Cancer Res. 2008 Nov 1;14(21):7158.

PMID:
18258665
[PubMed - indexed for MEDLINE]
Free Article
2.

[Evaluation of selected serum protein markers as early detectors of ovarian cancer].

Mrochem J, Sodowski K, Deja R, Walaszek-Gruszka A, Wojcieszek A, Kołosza Z, Chmura A, Czernik E, Masłyk B, Bartnik W, Cnota W.

Ginekol Pol. 2008 Apr;79(4):271-5. Polish.

PMID:
18592865
[PubMed - indexed for MEDLINE]
3.

Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer.

Gorelik E, Landsittel DP, Marrangoni AM, Modugno F, Velikokhatnaya L, Winans MT, Bigbee WL, Herberman RB, Lokshin AE.

Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):981-7.

PMID:
15824174
[PubMed - indexed for MEDLINE]
Free Article
4.

[The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].

Dong L, Chang XH, Ye X, Zhu LR, Zhao Y, Tian L, Cheng HY, Li XP, Zhang H, Liao QP, Fu TY, Cheng YX, Cui H.

Zhonghua Fu Chan Ke Za Zhi. 2008 Dec;43(12):931-6. Chinese.

PMID:
19134334
[PubMed - indexed for MEDLINE]
5.

Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.

Baron AT, Boardman CH, Lafky JM, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ.

Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):306-18. Erratum in: Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1583.

PMID:
15734951
[PubMed - indexed for MEDLINE]
Free Article
6.

Serum protein markers for early detection of ovarian cancer.

Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, Rutherford T, Yue L, Bray-Ward P, Ward DC.

Proc Natl Acad Sci U S A. 2005 May 24;102(21):7677-82. Epub 2005 May 12.

PMID:
15890779
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions.

Skates SJ, Horick N, Yu Y, Xu FJ, Berchuck A, Havrilesky LJ, de Bruijn HW, van der Zee AG, Woolas RP, Jacobs IJ, Zhang Z, Bast RC Jr.

J Clin Oncol. 2004 Oct 15;22(20):4059-66. Epub 2004 Sep 20.

PMID:
15381683
[PubMed - indexed for MEDLINE]
8.

A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer--a study of the OVCAD consortium.

Pils D, Tong D, Hager G, Obermayr E, Aust S, Heinze G, Kohl M, Schuster E, Wolf A, Sehouli J, Braicu I, Vergote I, Van Gorp T, Mahner S, Concin N, Speiser P, Zeillinger R.

BMC Cancer. 2013 Apr 3;13:178. doi: 10.1186/1471-2407-13-178.

PMID:
23551967
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Bead-based ELISA for validation of ovarian cancer early detection markers.

Scholler N, Crawford M, Sato A, Drescher CW, O'Briant KC, Kiviat N, Anderson GL, Urban N.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2117-24.

PMID:
16609024
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer.

Simon I, Liu Y, Krall KL, Urban N, Wolfert RL, Kim NW, McIntosh MW.

Gynecol Oncol. 2007 Jul;106(1):112-8. Epub 2007 May 8.

PMID:
17490732
[PubMed - indexed for MEDLINE]
11.

Early detection of head and neck cancer: development of a novel screening tool using multiplexed immunobead-based biomarker profiling.

Linkov F, Lisovich A, Yurkovetsky Z, Marrangoni A, Velikokhatnaya L, Nolen B, Winans M, Bigbee W, Siegfried J, Lokshin A, Ferris RL.

Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):102-7.

PMID:
17220337
[PubMed - indexed for MEDLINE]
Free Article
12.

Phase II biomarker trial of a multimarker diagnostic for ovarian cancer.

Edgell T, Martin-Roussety G, Barker G, Autelitano DJ, Allen D, Grant P, Rice GE.

J Cancer Res Clin Oncol. 2010 Jul;136(7):1079-88. doi: 10.1007/s00432-009-0755-5. Epub 2010 Jan 16.

PMID:
20082099
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Comparison of candidate serologic markers for type I and type II ovarian cancer.

Lu D, Kuhn E, Bristow RE, Giuntoli RL 2nd, Kjær SK, Shih IeM, Roden RB.

Gynecol Oncol. 2011 Sep;122(3):560-6. doi: 10.1016/j.ygyno.2011.05.039. Epub 2011 Jun 24.

PMID:
21704359
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence.

Havrilesky LJ, Whitehead CM, Rubatt JM, Cheek RL, Groelke J, He Q, Malinowski DP, Fischer TJ, Berchuck A.

Gynecol Oncol. 2008 Sep;110(3):374-82. doi: 10.1016/j.ygyno.2008.04.041. Epub 2008 Jun 27.

PMID:
18584856
[PubMed - indexed for MEDLINE]
15.

Osteopontin as a potential diagnostic biomarker for ovarian cancer.

Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW, Mok SC.

JAMA. 2002 Apr 3;287(13):1671-9.

PMID:
11926891
[PubMed - indexed for MEDLINE]
16.

Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection.

Berek JS, Bast RC Jr.

Cancer. 1995 Nov 15;76(10 Suppl):2092-6. Review.

PMID:
8635006
[PubMed - indexed for MEDLINE]
17.

Test of ovarian cancer multiplex xMAP technology panel.

Vrzalova J, Prazakova M, Novotny Z, Topolcan O, Casova M, Holubec L Jr.

Anticancer Res. 2009 Feb;29(2):573-6.

PMID:
19331205
[PubMed - indexed for MEDLINE]
Free Article
18.

The ROC 'n' role of the multiplex assay for early detection of ovarian cancer.

Nick AM, Sood AK.

Nat Clin Pract Oncol. 2008 Oct;5(10):568-9. doi: 10.1038/ncponc1214. Epub 2008 Aug 12.

PMID:
18695710
[PubMed]
19.

Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer.

Jackson D, Craven RA, Hutson RC, Graze I, Lueth P, Tonge RP, Hartley JL, Nickson JA, Rayner SJ, Johnston C, Dieplinger B, Hubalek M, Wilkinson N, Perren TJ, Kehoe S, Hall GD, Daxenbichler G, Dieplinger H, Selby PJ, Banks RE.

Clin Cancer Res. 2007 Dec 15;13(24):7370-9.

PMID:
18094419
[PubMed - indexed for MEDLINE]
Free Article
20.

Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer.

Brakora KA, Lee H, Yusuf R, Sullivan L, Harris A, Colella T, Seiden MV.

Gynecol Oncol. 2004 May;93(2):361-5.

PMID:
15099946
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk